Atea Pharmaceuticals (AVIR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members and executive team, including representatives from the independent auditor KPMG.
Stockholders were informed of meeting procedures, voting eligibility, and rules of conduct.
Board and executive committee updates
Three Class III directors were nominated for re-election to serve until 2029.
Board and executive team members were introduced, highlighting leadership continuity.
Shareholder proposals
Proposals included election of directors, ratification of KPMG as auditor for 2026, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Atea Pharmaceuticals
- BEM/RZR met Phase 3 endpoints, supporting NDA plans for HCV in 2027 and strong commercial prospects.AVIR
Q2 2026 - Phase 3 HCV trials advance toward 2026 readouts as R&D drives higher net loss and cash supports runway.AVIRQ1 2026
- Key votes include director elections, auditor ratification, and executive pay approval.AVIRProxy filing
- Proxy covers director elections, auditor ratification, and performance-based executive pay.AVIRProxy filing
- Phase III HCV and HEV programs advance, topline results in 2026, cash $301.8M, net loss $158.4M.AVIRQ4 2025
- Late-stage HCV and preclinical HEV programs advance with strong clinical and market momentum.AVIR44th Annual J.P. Morgan Healthcare Conference
- HCV Phase 2 results due December; $482.8M cash funds operations through 2027.AVIRQ3 2024
- Pivotal COVID-19 and HCV trial results due late 2024; $502.2M cash funds operations into 2027.AVIRQ2 2024
- Strong phase II HCV results and a pivotal COVID-19 trial set up major milestones for late 2024.AVIRJefferies 2024 Global Healthcare Conference